Press release content from Business Wire. The AP news staff was not involved in its creation.
PureTech Adds Bharatt Chowrira, PureTech’s President and Chief of Business and Strategy, to Board of Directors
January 29, 2021 GMT
PureTech announced the appointment of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors. Dr. Chowrira has served as PureTech’s President and Chief of Business and Strategy since March 2017. (Photo: Business Wire)
PureTech announced the appointment of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors. Dr. Chowrira has served as PureTech’s President and Chief of Business and Strategy since March 2017. (Photo: Business Wire)
PureTech Adds Bharatt Chowrira, PureTech s President and Chief of Business and Strategy, to Board of Directors
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ( PureTech or the Company ), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announces the appointment of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors as an executive director. Dr. Chowrira has served as PureTech s President and Chief of Business and Strategy since March 2017 and will continue in that role as an executive director of the Company. Dr. Chowrira s appointment is effective from February 1, 2021. Bharatt has made a big impact since joining PureTech in 2017 and he continues to make key contributions as we advance our clinical pipeline toward key value-driving milestones, said Daphne Zohar, Founder and Chief Executive Officer of PureTech
New gene-based vaccine strategy receives grant from the Bill & Melinda Gates Foundation
The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation.
The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021.
The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic.
Preliminary tests of the vaccines stability and potency at different temperatures revealed that AAVCOVID candidates remained potent and effective when stored at room temperature for up to one month. This room temperature stability and the fact AAVCOVID vaccines do not require cold-chain freezer storage, could enable this AAV-based platform to develop a vaccine for COVID-19 and other diseases for developing countries without the n
E-Mail
The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation.
The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021.
The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic.
Preliminary tests of the vaccines stability and potency at different temperatures revealed that AAVCOVID candidates remained potent and effective when stored at room temperature for up to one month. This room temperature stability and the fact AAVCOVID vaccines do not require cold-chain freezer storage, could enable this AAV-based platform to develop a vaccine for COVID-19 and other diseases for developing countries without the necessary cooling infrastructure some vaccines require.
Vacunas contra Covid 19: Una oportunidad histórica « Diario La Capital de Mar del Plata lacapitalmdp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lacapitalmdp.com Daily Mail and Mail on Sunday newspapers.